Bioventrix

Bioventrix company information, Employees & Contact Information

Explore related pages

Related company profiles:

BioVentrix, Inc. a specialty medical device company serving cardiothoracic surgeons and their patients with lifesaving heart failure therapies. BioVentrix technologies aim to improve cardiac function by directly addressing LV dilation. The BioVentrix Revivent System is designed to support a minimally invasive procedure to treat a dilated left ventricle of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and extensive left ventricular scar, who have a suboptimal response to guideline-directed medical therapy. The procedure uses myocardial micro-anchor implants to reconstruct the dilated left ventricle to produce a more efficient chamber. BioVentrix offers benefits to all stakeholders in heart failure: Patient – improved survival and QOL by treating the underlying cause of HF less invasively Payor – reduced hospitalizations and avoidance of more expensive, highly invasive procedures like transplant and LVAD Provider – become a pioneer in heart failure and offer unique solutions to your patients, in the growing and most expensive disease state in the world

Company Details

Employees
21
Address
120 Forbes Blvd, Mansfield,massachusetts 02048,united States
Phone
925-830-1000
Email
in****@****rix.com
Industry
Medical Device
HQ
Mansfield, Massachusetts
Looking for a particular Bioventrix employee's phone or email?

Bioventrix Questions

News

BioVentrix Announces the Appointment of Pedro Marques as VP of Sales in Europe - PR Newswire

BioVentrix Announces the Appointment of Pedro Marques as VP of Sales in Europe PR Newswire

BioVentrix Announces Germany's First Revivent TC TransCatheter Ventricular Enhancement Procedure - Diagnostic and Interventional Cardiology

BioVentrix Announces Germany's First Revivent TC TransCatheter Ventricular Enhancement Procedure Diagnostic and Interventional Cardiology

BioVentrix lassos $48.5M to take its ventricle-reshaping heart failure implants to the FDA - Fierce Biotech

BioVentrix lassos $48.5M to take its ventricle-reshaping heart failure implants to the FDA Fierce Biotech

BioVentrix Has Developed a Unique Way to Improve Heart Functionality - Medical Device and Diagnostic industry

BioVentrix Has Developed a Unique Way to Improve Heart Functionality Medical Device and Diagnostic industry

BioVentrix receives FDA expanded access program approval for ischemic heart failure treatment system - Cardiac Rhythm News

BioVentrix receives FDA expanded access program approval for ischemic heart failure treatment system Cardiac Rhythm News

FDA expands access to BioVentrix ischemic heart failure treatment - MassDevice

FDA expands access to BioVentrix ischemic heart failure treatment MassDevice

BioVentrix Appoints Raymond W. Cohen as Chairman of the Board - citybiz

BioVentrix Appoints Raymond W. Cohen as Chairman of the Board citybiz

BioVentrix Names Jim Dillon President and CEO - Business Wire

BioVentrix Names Jim Dillon President and CEO Business Wire

BioVentrix® Closes $48.5 Million Series A Financing - PR Newswire

BioVentrix® Closes $48.5 Million Series A Financing PR Newswire

BiVACOR Names Former BioVentrix Leader Jim Dillon as New CEO - Medical Product Outsourcing

BiVACOR Names Former BioVentrix Leader Jim Dillon as New CEO Medical Product Outsourcing

BioVentrix Announces First Pre-Clinical Use of Revivent-TC System - Diagnostic and Interventional Cardiology

BioVentrix Announces First Pre-Clinical Use of Revivent-TC System Diagnostic and Interventional Cardiology

BioVentrix snatches up MateraCor for a hydrogel-based approach to heart failure - Fierce Biotech

BioVentrix snatches up MateraCor for a hydrogel-based approach to heart failure Fierce Biotech

BioVentrix expands heart failure treatment portfolio with MateraCor acquisition - MassDevice

BioVentrix expands heart failure treatment portfolio with MateraCor acquisition MassDevice

BioVentrix CE Mark Extended for Less Invasive Heart Failure Ventricular Enhancement - Diagnostic and Interventional Cardiology

BioVentrix CE Mark Extended for Less Invasive Heart Failure Ventricular Enhancement Diagnostic and Interventional Cardiology

BiVacor picks former BioVentrix CEO for its corner office - MassDevice

BiVacor picks former BioVentrix CEO for its corner office MassDevice

BioVentrix® Names Dr. Ori Ben-Yehuda as Chief Medical Officer - PR Newswire

BioVentrix® Names Dr. Ori Ben-Yehuda as Chief Medical Officer PR Newswire

First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial - Diagnostic and Interventional Cardiology

First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial Diagnostic and Interventional Cardiology

BioVentrix appoints Jim Dillon president and CEO - MassDevice

BioVentrix appoints Jim Dillon president and CEO MassDevice

Top Bioventrix Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant